OREANDA-NEWS. Amgen announced today the early tender results of its previously announced seven separate private offers to exchange certain specified series of its outstanding senior notes (collectively, the "Old Notes") for new Senior Notes due 2048 (the "New 2048 Notes") and new Senior Notes due 2051, as applicable.

The Exchange Offers consist of the following:

          (a) (i) an offer to exchange any and all 6.375% Senior Notes due 2037;
               (ii) an offer to exchange any and all 6.90% Senior Notes due 2038; and
               (iii) an offer to exchange any and all 6.40% Senior Notes due 2039;

in each case, for New 2048 Notes (collectively, the "2048 Exchange Offers"); and

          (b) (i) an offer to exchange the 5.75% Senior Notes due 2040;
               (ii) an offer to exchange the 5.65% Senior Notes due 2042;  
               (iii) an offer to exchange the 5.375% Senior Notes due 2043; and
               (iv) an offer to exchange the 5.15% Senior Notes due 2041;

in each case, for New 2051 Notes (collectively, the "2051 Exchange Offers"), provided that the aggregate principal amount of New 2051 Notes to be issued in the 2051 Exchange Offers shall not exceed $7,100,000,000less the aggregate principal amount of New 2048 Notes to be issued pursuant to the 2048 Exchange Offers (such amount, the "Maximum 2051 Notes Exchange Cap").

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.